Cargando…

Profiling of plasma biomarkers in the context of memory assessment in a tertiary memory clinic

Plasma biomarkers have shown promising performance in research cohorts in discriminating between different stages of Alzheimer’s disease (AD). Studies in clinical populations are necessary to provide insights on the clinical utility of plasma biomarkers before their implementation in real-world sett...

Descripción completa

Detalles Bibliográficos
Autores principales:	Bucci, Marco, Bluma, Marina, Savitcheva, Irina, Ashton, Nicholas J., Chiotis, Konstantinos, Matton, Anna, Kivipelto, Miia, Di Molfetta, Guglielmo, Blennow, Kaj, Zetterberg, Henrik, Nordberg, Agneta
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Nature Publishing Group UK 2023
Materias:	Article
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10368630/ https://www.ncbi.nlm.nih.gov/pubmed/37491358 http://dx.doi.org/10.1038/s41398-023-02558-4

Ejemplares similares

Regional Disconnection in Alzheimer Dementia and Amyloid-Positive Mild Cognitive Impairment: Association Between EEG Functional Connectivity and Brain Glucose Metabolism
por: Smailovic, Una, et al.
Publicado: (2020)

Clinical impact of [(18)F]flutemetamol PET among memory clinic patients with an unclear diagnosis
por: Leuzy, Antoine, et al.
Publicado: (2019)

Tracking reactive astrogliosis in autosomal dominant and sporadic Alzheimer’s disease with multi-modal PET and plasma GFAP
por: Chiotis, Konstantinos, et al.
Publicado: (2023)

Amyloid PET in European and North American cohorts; and exploring age as a limit to clinical use of amyloid imaging
por: Chiotis, Konstantinos, et al.
Publicado: (2015)

Spatial Normalization of (18)F-Flutemetamol PET Images Using an Adaptive Principal-Component Template
por: Lilja, Johan, et al.
Publicado: (2019)

[(18)F]THK5317 imaging as a tool for predicting prospective cognitive decline in Alzheimer’s disease
por: Chiotis, Konstantinos, et al.
Publicado: (2020)

Alzheimer’s disease profiled by fluid and imaging markers: tau PET best predicts cognitive decline
por: Bucci, Marco, et al.
Publicado: (2021)

Alzheimer’s disease biomarker profiling in a memory clinic cohort without common comorbidities
por: Daniilidou, Makrina, et al.
Publicado: (2023)

Longitudinal tau and metabolic PET imaging in relation to novel CSF tau measures in Alzheimer’s disease
por: Leuzy, Antoine, et al.
Publicado: (2019)

Clinical impact of (18)F-FDG-PET among memory clinic patients with uncertain diagnosis
por: Perini, Giulia, et al.
Publicado: (2020)

Pittsburgh compound B imaging and cerebrospinal fluid amyloid-β in a multicentre European memory clinic study
por: Leuzy, Antoine, et al.
Publicado: (2016)

Astrocyte Signature in Alzheimer’s Disease Continuum through a Multi-PET Tracer Imaging Perspective
por: Fontana, Igor C., et al.
Publicado: (2023)

Saliva Neurofilament Light Chain Is Not a Diagnostic Biomarker for Neurodegeneration in a Mixed Memory Clinic Population
por: Gleerup, Helena Sophia, et al.
Publicado: (2021)

Spitting image: can saliva biomarkers reflect Alzheimer's disease?
por: Ashton, Nicholas J., et al.
Publicado: (2021)

Imaging in-vivo tau pathology in Alzheimer’s disease with THK5317 PET in a multimodal paradigm
por: Chiotis, Konstantinos, et al.
Publicado: (2016)

β-Amyloid, Tau, Neurodegeneration Classification and Eligibility for Anti-amyloid Treatment in a Memory Clinic Population
por: Rosenberg, Anna, et al.
Publicado: (2022)

The taxonomy of subjective cognitive decline: proposal and first clinical evidence from the Geneva memory clinic cohort
por: Ribaldi, Federica, et al.
Publicado: (2023)

Salivary Biomarkers for Alzheimer’s Disease and Related Disorders
por: Ashton, Nicholas J., et al.
Publicado: (2019)

Blood neurofilament light in remote settings: Alternative protocols to support sample collection in challenging pre‐analytical conditions
por: Simrén, Joel, et al.
Publicado: (2021)

Editorial: Blood Biomarkers of Neurodegenerative Diseases
por: Karikari, Thomas K., et al.
Publicado: (2022)

Acute hyperglycaemia leads to altered frontal lobe brain activity and reduced working memory in type 2 diabetes
por: Backeström, Anna, et al.
Publicado: (2021)

Clinical validity of increased cortical binding of tau ligands of the THK family and PBB3 on PET as biomarkers for Alzheimer’s disease in the context of a structured 5-phase development framework
por: Chiotis, Konstantinos, et al.
Publicado: (2021)

Association of plasma P-tau181 with memory decline in non-demented adults
por: Therriault, Joseph, et al.
Publicado: (2021)

Longitudinal association between astrocyte function and glucose metabolism in autosomal dominant Alzheimer’s disease
por: Carter, Stephen F., et al.
Publicado: (2018)

Is it time for biomarker-based diagnostic criteria for prodromal Alzheimer's disease?
por: Blennow, Kaj, et al.
Publicado: (2010)

The past and the future of Alzheimer's disease CSF biomarkers—a journey toward validated biochemical tests covering the whole spectrum of molecular events
por: Blennow, Kaj, et al.
Publicado: (2015)

The Past and the Future of Alzheimer’s Disease Fluid Biomarkers(1)
por: Blennow, Kaj, et al.
Publicado: (2018)

Moving fluid biomarkers for Alzheimer’s disease from research tools to routine clinical diagnostics
por: Zetterberg, Henrik, et al.
Publicado: (2021)

Progression to dementia in memory clinic patients with mild cognitive impairment and normal β-amyloid
por: Rosenberg, Anna, et al.
Publicado: (2019)

Blood Biomarkers for Alzheimer’s Disease in Down Syndrome
por: Montoliu-Gaya, Laia, et al.
Publicado: (2021)

Plasma biomarkers for Alzheimer’s disease: a field-test in a memory clinic
por: Altomare, Daniele, et al.
Publicado: (2023)

Tau positron emission tomography imaging in tauopathies: The added hurdle of off-target binding
por: Lemoine, Laetitia, et al.
Publicado: (2018)

Growth differentiation factor 15 increases in both cerebrospinal fluid and serum during pregnancy
por: Andersson-Hall, Ulrika, et al.
Publicado: (2021)

Research diagnostic criteria for Alzheimer’s disease: findings from the LipiDiDiet randomized controlled trial
por: Rosenberg, Anna, et al.
Publicado: (2021)

The Dietary Carbohydrate/Fat-Ratio and Cognitive Performance: Panel Analyses in Older Adults at Risk for Dementia
por: Norgren, Jakob, et al.
Publicado: (2023)

Lessons from Multicenter Studies on CSF Biomarkers for Alzheimer's Disease
por: Mattsson, Niklas, et al.
Publicado: (2010)

Cerebrospinal Fluid Analysis Should Be Considered in Patients with Cognitive Problems
por: Zetterberg, Henrik, et al.
Publicado: (2010)

Neuroinflammation Screening in Immunotherapy Trials against Alzheimer's Disease
por: Andreasen, Niels, et al.
Publicado: (2010)

Update on ultrasensitive technologies to facilitate research on blood biomarkers for central nervous system disorders
por: Andreasson, Ulf, et al.
Publicado: (2016)

24-month intervention with a specific multinutrient in people with prodromal Alzheimer's disease (LipiDiDiet): a randomised, double-blind, controlled trial
por: Soininen, Hilkka, et al.
Publicado: (2017)

Cannot write session to /tmp/vufind_sessions/sess_lk31daimal2qhobrc7g8afv1sp